DCTH vs. CLPT, QIPT, TELA, OBIO, STIM, KRMD, ALUR, BLUA, DRTS, and BWAY
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), TELA Bio (TELA), Orchestra BioMed (OBIO), Neuronetics (STIM), KORU Medical Systems (KRMD), Allurion Technologies (ALUR), BlueRiver Acquisition (BLUA), Alpha Tau Medical (DRTS), and BrainsWay (BWAY). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
ClearPoint Neuro has higher revenue and earnings than Delcath Systems. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
In the previous week, ClearPoint Neuro had 2 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for ClearPoint Neuro and 2 mentions for Delcath Systems. ClearPoint Neuro's average media sentiment score of 0.60 beat Delcath Systems' score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the news media.
Delcath Systems presently has a consensus price target of $18.50, indicating a potential upside of 220.62%. ClearPoint Neuro has a consensus price target of $12.00, indicating a potential upside of 102.02%. Given Delcath Systems' higher probable upside, research analysts plainly believe Delcath Systems is more favorable than ClearPoint Neuro.
ClearPoint Neuro has a net margin of -92.21% compared to Delcath Systems' net margin of -2,308.86%. ClearPoint Neuro's return on equity of -83.94% beat Delcath Systems' return on equity.
Delcath Systems and ClearPoint Neuro both received 20 outperform votes by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 20.00% of users gave Delcath Systems an outperform vote.
Delcath Systems has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 17.9% of Delcath Systems shares are held by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
ClearPoint Neuro beats Delcath Systems on 10 of the 16 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Delcath Systems Competitors List
Related Companies and Tools
